Industry News_News_ Zhongshan Haihong Pharmaceutical Co., Ltd.

Indications for biologics are rapidly expanding to include osteoporosis, multiple sclerosis, asthma, anti-infectives, cardiovascular and many other areas

Original title: An article to read the development prospects of China's biologics market Source; Sina Pharmaceutical News By: E Drug Manager Biologics is one of the fastest growing sub-sectors in the pharmaceutical industry in recent years, and the global market size is expected to rise from $202 billion in 2016 to $326 billion in 2022, with a compound annual growth rate of 3%. China's market size grew from $62.7 billion in 2012 to $152.7 billion in 2016, with a compound annual growth rate of 24.9%.Frost & Sullivan expects China's biologics to maintain a compound annual growth rate of 16.4% from 2016 to 2021, reaching a market size of $326.9 billion by 2021. 1. Biologics will account for 30% in 2022 From the global drug sales ranking in the past few years, it can be seen that the proportion of biologics in the top 10 drugs in sales has been increasing year by year. 2017, seven are biomacromolecules, fully demonstrating the market's recognition of biologics. For the future market, Evaluate Pharma predicts that biologics will continue to maintain a strong market position, with the market share of biologics expected to rise from 25% ($202 billion) in 2016 to 30% ($326 billion) in 2022. Leading global pharmaceutical R&D companies are increasingly focused on biologic macromolecules, with more than 900 biologics in development for the world's 18 largest pharmaceutical companies alone. The investment of resources and funding in biologics R&D, continuous technological advances, and increasing awareness of disease have enabled pharmaceutical companies to continue to develop innovative biologics with superior efficacy and safety. The rapid growth of biologics is driven by three main factors: rapid expansion of indications, with the indications of biologics represented by antibody drugs rapidly expanding to include osteoporosis, multiple sclerosis, asthma, anti-infectives, cardiovascular and many other areas; accelerated progress of new drug launches, with the FDA approving a record high of 10 new antibody drugs in 2017; and the gradual expiration of patents for heavyweight biologics, with annual sales expected to combined $70-80 billion in biologics will lose patent protection in the next five years, which presents a significant opportunity for the development of biosimilars. Driven by increased healthcare spending, enhanced R&D capabilities, positive government policy changes and increased capital investment, China's biologics market has been growing rapidly over the past several years, outpacing the global market, and is expected to continue to grow strongly in the future. According to Frost & Sullivan, the market size of biologics in China grew from RMB 62.7 billion in 2012 to RMB 152.7 billion in 2016, with a compound annual growth rate of 24.9%. It is expected to grow at a CAGR of 16.4% from 2016 to 2021, reaching a market size of RMB 326.9 billion in 2021, presenting huge opportunities for Chinese biologics players. Meanwhile, antibody drugs, as an emerging segment of biologics, will see rapid growth, according to a Frost & Sullivan report, the market size of monoclonal antibodies in China increased from RMB 3.5 billion in 2012 to RMB 9.1 billion in 2016, with a CAGR of 26.8%. It is estimated to continue growing at a CAGR of 25.0% from 2016 to 2021, reaching a market size of RMB 27.6 billion in 2021. Recommendation: Our APIs and intermediates for the treatment of osteoporosis, multiple sclerosis, asthma, anti-infection, cardiovascular, tumor and other diseases are Anseritrapib, Vandetanib, Ospemifene, Minophosphate, etc. For more details, please browse our catalog or call us.

→

Ann Rheum Dis: Patients with psoriatic arthritis need to prevent cardiovascular events

Literature title: Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Literature source: Ann Rheum Dis 2015 Oct 22 To assess the incidence and risk factors for cardiovascular events in patients with psoriatic arthritis (PsA). Researchers conducted a cohort study in which subjects were recruited from a large psoriatic arthritis (PsA) hospital for a follow-up survey between 1978-2013. Participants did assessments at 6-12 month intervals according to a standard protocol. Information collected included demographics, lifestyle habits, medical history, medication use history, and outcomes associated with psoriatic arthritis (PsA). The primary outcome was a composite of primary cardiovascular endpoints, including myocardial infarction, ischemic stroke, angioplasty, and cardiovascular death. The association between characteristics of disease activity and the occurrence of cardiovascular events was assessed using a Cox proportional risk model. Researchers analyzed 1091 cases of prostate-specific antigen. During the follow-up period, a total of 104 cardiovascular events occurred. A significant proportion of patients had a cardiovascular event (19.8% of patients, aged 70 years; 30.1%, aged 80 years). In the last decades (from 1978-2013), no trend in the presence of cardiovascular events was observed (p=0.73). In multivariate analysis, the following variables were independent predictors of major cardiovascular events: hypertension (relative risk ratio (RR) 1.81,P = 0.015), diabetes mellitus (RR 2.72,P<0.001) and number of finger shapes (RR 1.20,P<0.001). Sedimentation rate was a significant predictor for female patients only (RR = 1.83,P = 0.02). Patients with psoriatic arthritis had a significant increase in cardiovascular events during the disease progression. The increased cardiovascular risk correlated with traditional cardiovascular risk factors and disease activity. We produce APIs and intermediates for the treatment of psoriasis, Apoest and Apoest intermediates, if you need them, please feel free to contact us!

→

Alendronate improves bone density in patients with cystic fibrosis

Long-term complications of cystic fibrosis include osteoporosis and fragility fractures, but there are few data on effective treatment strategies, especially in younger patients. We investigated the treatment of low bone mineral density in children, adolescents and young cystic fibrosis patients. A study by Italian scholars showed that alendronate improved bone density in patients with cystic fibrosis. This multicenter randomized controlled study was conducted in two phases. Patients aged 5-30 years with cystic fibrosis and low bone density were first enrolled from 10 cystic fibrosis treatment centers in Italy. The phase I trial was a 12-month open study looking at the effects of adequate calcium intake and osteodiol. The Phase II study was a 12-month double-blind randomized placebo-controlled parallel group study of the safety and efficacy of oral alendronate in patients with less than 5% increase in bone mineral density from the Phase I study. Patients were randomly assigned to the oral alendronate and placebo groups in a double-blind study. We used dual-energy X-rays to observe BMD at baseline and at 6 months of treatment, corrected for weight, and assessed lumbar spine BMD. We assessed bone turnover index and other laboratory parameters every 3-6 months. The primary study endpoint was the mean increase in lumbar spine BMD in the intention-to-treat population. The results showed that we screened 540 cases and included 171 of these patients (mean age 13.8 years, range 5-30 years). During the observation period, 43 patients (25%) ingested calcium and osteodiol to increase BMD by more than 5%. The remaining 128 patients were entered into a randomized group trial. Patients in the alendronate group increased BMD by 16.3% (N=65) compared to 3.1% in the placebo group (N=63, p=0.001). 19 of 57 young patients (33.3%) treated with alendronate achieved an age-normal BMD Z-score. During the observation period, moderate hypercalciuria occurred in 5 patients, all of whom improved after a short interruption of osteodiol therapy. During the randomized study period, hypothermia occurred in 1 patient taking alendronate but not in patients in the placebo group. There were also no significant differences between the treatment and placebo groups in terms of other adverse effects.

→

FDA approves marketing of a diabetes drug, liragliptin

The U.S. Food and Drug Administration approved on the 2nd a treatment for type II diabetes oral tablet Tradjenta (generic name "Liragliptin") on the market, Liragliptin can be used to improve the ability of type II diabetes patients to control blood sugar. Type II diabetes, also known as adult-onset diabetes, is the most common form of diabetes and is characterized by insulin resistance, meaning that the body is able to produce insulin, but the body's tissues are insensitive to the effects of insulin and normal amounts of insulin do not have a normal hypoglycemic effect. By inhibiting dipeptidyl peptidase-4, liragliptin raises the level of a hormone that stimulates insulin release, which in turn improves blood sugar control in those who take it. The FDA said the drug's safety and effectiveness were demonstrated in eight double-blind clinical trials involving about 3,800 patients with type II diabetes, with major side effects including upper respiratory infections, runny nose, sore throat, muscle pain and headache. Produced by Boehringer Ingelheim Pharmaceuticals in Connecticut, USA, Liragliptin can be taken alone or in combination with other available medications.

→

Why should I wear a mask? What do I need to pay attention to when using a mask?

The correct way to wear a mask Usually the disposable masks we buy in pharmacies are medical general surgical masks, which have two sides, the darker side - the blue side faces outward, and the lighter side faces inward, close to our face. Not only that, the mask is also divided into upper and lower, the side with the metal strip inside that feels harder is the upper end, which is close to the bridge of the nose when worn. After understanding the basic structure of the mask, let's learn how to wear the mask correctly. First, wash: First, wash your hands to avoid contamination of the inner surface of the mask by unclean hands; Second, hang: the mask across the face on the mouth and nose, using both hands to hang the rope at both ends of the ear; Third, pull: as shown in the figure below, both hands simultaneously pull the folds of the mask in the up and down direction, so that the mask can completely cover the mouth, nose and chin; Fourth, pressure: Finally, use the index fingers of both hands to press the metal strips on both sides of the bridge of the nose, so that the upper end of the mask can be close to the bridge of the nose. In addition, we need to remind you that: after wearing the mask, avoid frequent touching the mask to prevent reducing the protective effect; after taking off the mask, put it into a tape or paper bag, then put it into a covered garbage can and dispose of it, and wash your hands in time; do not reuse disposable masks. The correct way to wear the mask Precautions for masks Length of use From the point of view of human physiological structure, because the human nasal mucosa blood circulation is very vigorous, the nasal cavity channels and very tortuous, nasal hair structure a filtering "barrier". When the air is inhaled into the nostrils, the airflow forms a vortex in the winding channel, so that the airflow inhaled into the nasal cavity is heated. Tests have shown that when cold air at -7°C is inhaled into the lungs through the nose, the airflow has been heated to 28.8°C, which is very close to the temperature of the human body. If you wear a mask for a long time, it will make the nasal mucosa become fragile and lose the original physiological function of the nasal cavity, so you cannot wear a mask for a long time. The mask can only be worn in a special environment, such as in a crowded, air-deficient place. Of course, walking in the field, in order to resist the sand and cold, or in the environment with air pollution activities, it is necessary to wear a mask, but the time should not be too long. In addition, during the flu season, you should also wear a mask when going to public places where there may be a large number of pathogenic bacteria. Wearing a mask is only one of the ways to prevent respiratory infections, the most important thing is to maintain good habits. Cleaning and maintenance The outer layer of the mask often accumulates a lot of dust, bacteria and other dirt in the outside air, while the inner layer blocks the exhaled bacteria, saliva, therefore, the two sides can not be used alternately, otherwise the outer layer will be stained with dirt in the direct close to the face when inhaled into the body, and become a source of infection. When the mask is not worn, it should be folded into a clean envelope and folded inward on the side that is close to the nose and mouth, do not just stuff it into a pocket or hang it around the neck.

→